Contact
searchSearch
HMP Global
Login

Conference Coverage

Conference Coverage
Innovations in Relapsed or Refractory Multiple Myeloma Management
09/21/2026
Rebecca Amrick
At the National Comprehensive Cancer Network 2026 Annual Congress: Hematologic Malignancies, panelists discussed innovations in treating relapsed or refractory multiple myeloma and strategies to improve disease management.
At the National Comprehensive Cancer Network 2026 Annual Congress: Hematologic Malignancies, panelists discussed innovations in treating relapsed or refractory multiple myeloma and strategies to improve disease management.
At the National Comprehensive...
09/21/2026
Journal of Clinical Pathways
Conference Coverage
Managing Treatment Toxicity Among Patients With Chronic Myeloid Lymphoma
09/21/2026
Rebecca Amrick
Jenna Moran, MSN, FNP-BC, outlined strategies for managing tyrosine kinase inhibitor–related toxicities in patients with chronic myeloid leukemia during a session at the National Comprehensive Cancer Network 2026 Annual Congress.
Jenna Moran, MSN, FNP-BC, outlined strategies for managing tyrosine kinase inhibitor–related toxicities in patients with chronic myeloid leukemia during a session at the National Comprehensive Cancer Network 2026 Annual Congress.
Jenna Moran, MSN, FNP-BC,...
09/21/2026
Journal of Clinical Pathways
Conference Coverage
De-Escalating TKI Therapy Based on Risk and Response for Patients With CML
09/18/2026
Rebecca Amrick
At the National Comprehensive Cancer Network 2026 Annual Congress: Hematologic Malignancies, Vivian G. Oehler, MD, shared insights on de-escalating tyrosine kinase inhibitor (TKI) therapy among patients with chronic myeloid leukemia (CML)...
At the National Comprehensive Cancer Network 2026 Annual Congress: Hematologic Malignancies, Vivian G. Oehler, MD, shared insights on de-escalating tyrosine kinase inhibitor (TKI) therapy among patients with chronic myeloid leukemia (CML)...
At the National Comprehensive...
09/18/2026
Journal of Clinical Pathways
Conference Coverage
Using Real-World Data to Improve HRR Testing Rates Among Patients With mCRPC
07/17/2026
Andy Osterland, PharmD, MS
Andy Osterland, PharmD, MS, discusses real-world patterns of homologous recombination repair (HRR) testing among patients with metastatic castration-resistant prostate cancer (mCRPC), identifying gaps in testing rates and patient access.
Andy Osterland, PharmD, MS, discusses real-world patterns of homologous recombination repair (HRR) testing among patients with metastatic castration-resistant prostate cancer (mCRPC), identifying gaps in testing rates and patient access.
Andy Osterland, PharmD, MS,...
07/17/2026
Journal of Clinical Pathways
Jessica Paulus Headshot
Conference Coverage
Distress Thermometer Scores Highlight Association Between Psychosocial Distress and Survival Outcomes for Cancer Patients
07/13/2026
Jessica Paulus, ScD
Jessica Paulus, ScD, discusses the association between psychosocial distress and survival outcomes among patients with breast, colorectal, and lung cancer.
Jessica Paulus, ScD, discusses the association between psychosocial distress and survival outcomes among patients with breast, colorectal, and lung cancer.
Jessica Paulus, ScD, discusses...
07/13/2026
Journal of Clinical Pathways
Jessica Paulus Headshot
Conference Coverage
Closing the Gap Between Clinical Guideline Updates and Real-World Adoption for HER2-Low Therapies
06/17/2026
Jessica Paulus, ScD
Jessica Paulus, ScD, discusses the impact of education on increasing rates of human epidermal growth factor receptor 2 (HER2)-low therapy for patients with metastatic breast cancer.
Jessica Paulus, ScD, discusses the impact of education on increasing rates of human epidermal growth factor receptor 2 (HER2)-low therapy for patients with metastatic breast cancer.
Jessica Paulus, ScD, discusses...
06/17/2026
Journal of Clinical Pathways
Headshot of Dr. Andy Osterland
Conference Coverage
Using Patient Characteristics and Treatment History to Inform Treatment Plans for Patients With Gene-Mutated MCRPC
06/15/2026
Andy Osterland, PharmD, MS
Andy Osterland, PharmD, MS, discusses a real-world study of patients with metastatic castration-resistant prostate cancer (MCRPC) who were treated with talazoparib plus enzalutamide and the regimen’s impact on homologous recombination repair...
Andy Osterland, PharmD, MS, discusses a real-world study of patients with metastatic castration-resistant prostate cancer (MCRPC) who were treated with talazoparib plus enzalutamide and the regimen’s impact on homologous recombination repair...
Andy Osterland, PharmD, MS,...
06/15/2026
Journal of Clinical Pathways
Metastatic Prostate Cancer
Conference Coverage
Closing the Gap in HRR Testing for Metastatic Prostate Cancer in Community Oncology
06/04/2026
Helen Latimer, MPH
Helen Latimer, MPH, discusses new real-world evidence showing increased homologous recombination repair (HRR) genetic testing among patients with metastatic prostate cancer and the potential of electronic health record (HER)-driven clinical...
Helen Latimer, MPH, discusses new real-world evidence showing increased homologous recombination repair (HRR) genetic testing among patients with metastatic prostate cancer and the potential of electronic health record (HER)-driven clinical...
Helen Latimer, MPH, discusses...
06/04/2026
Journal of Clinical Pathways
Conference Coverage
Community-Engaged Strategies Reduce Cancer Care Delays and Advance Health Equity
03/27/2026
Hannah Musick
A nationwide, community-engaged cancer care initiative shows that coordinated workflows, patient navigation, and targeted social determinants of health interventions can improve treatment adherence, patient satisfaction, and equity in access...
A nationwide, community-engaged cancer care initiative shows that coordinated workflows, patient navigation, and targeted social determinants of health interventions can improve treatment adherence, patient satisfaction, and equity in access...
A nationwide, community-engaged...
03/27/2026
Journal of Clinical Pathways
Conference Coverage
Targeted Education Improves Cancer Pain Management in Community Hospitals
03/27/2026
Grace Taylor, MS, MA
A brief, National Comprehensive Cancer Network (NCCN)-guided educational session markedly improved hospitalists’ confidence and evidence-based cancer pain management practices in a community hospital setting.
A brief, National Comprehensive Cancer Network (NCCN)-guided educational session markedly improved hospitalists’ confidence and evidence-based cancer pain management practices in a community hospital setting.
A brief, National Comprehensive...
03/27/2026
Journal of Clinical Pathways

Special Reports

Special Report
Advancing a Standardized Economic Framework to Power Oncology Pathways: Methods and Model Development From Phase II of the Predictable Cost of Care Working Group
04/23/2026
Edward Arrowsmith, MD; Alan J. Balch, PhD, MSc; Vishnukamal Golla, MD, MPH; Andrew Hertler, MD, FACP; David Jackman, MD; Olaf Lodbrok, MS, MBA; Lalan Wilfong, MD; Gordon Kuntz; Carole Tremonti, RN, MBA
As cancer therapies expand and costs rise, oncology pathway developers need consistent, transparent methods to compare treatment options beyond drug acquisition costs. Building on Phase I’s consensus on relevant cost domains, the Phase II PCC...
As cancer therapies expand and costs rise, oncology pathway developers need consistent, transparent methods to compare treatment options beyond drug acquisition costs. Building on Phase I’s consensus on relevant cost domains, the Phase II PCC...
As cancer therapies expand and...
04/23/2026
Journal of Clinical Pathways
Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
08/15/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
08/15/2025
Journal of Clinical Pathways
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
08/15/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
08/15/2025
Journal of Clinical Pathways
Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
06/12/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
06/12/2025
Journal of Clinical Pathways
Page 1
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
02/19/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
02/19/2025
Journal of Clinical Pathways
JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Robin T. Zon, MD, FACP, FASCO; Gordon Kuntz; Winston Wong, PharmD
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use